Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · IEX Real-Time Price · USD
7.06
-0.09 (-1.26%)
At close: Apr 18, 2024, 4:00 PM
6.90
-0.16 (-2.27%)
After-hours: Apr 18, 2024, 6:49 PM EDT
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for FULC stock have an average target of 13.17, with a low estimate of 6.00 and a high estimate of 17. The average target predicts an increase of 86.54% from the current stock price of 7.06.
Analyst Consensus: Buy
* Price targets were last updated on Mar 13, 2024.
Analyst Ratings
The average analyst rating for FULC stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 1 | 2 | 3 | 3 |
Hold | 4 | 4 | 4 | 4 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 7 | 8 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Initiates $14 | Buy | Initiates | $14 | +98.30% | Mar 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $17 | Strong Buy | Maintains | $14 → $17 | +140.79% | Feb 28, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $13 → $15 | Buy | Maintains | $13 → $15 | +112.46% | Feb 28, 2024 |
Goldman Sachs | Goldman Sachs | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -15.01% | Jan 26, 2024 |
Goldman Sachs | Goldman Sachs | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -15.01% | Jan 25, 2024 |
Financial Forecast
Revenue This Year
1.96M
from 2.81M
Decreased by -30.30%
Revenue Next Year
13.60M
from 1.96M
Increased by 595.81%
EPS This Year
-1.78
from -1.59
EPS Next Year
-1.74
from -1.78
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 4.1M | 45.0M | 96.8M | 168.9M | 226.9M |
Avg | 2.0M | 13.6M | 66.2M | 164.1M | 220.5M |
Low | n/a | n/a | 15.0M | 157.7M | 211.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 47.6% | 2,203.1% | 611.3% | 155.2% | 38.3% |
Avg | -30.3% | 595.8% | 386.6% | 147.9% | 34.4% |
Low | - | - | 10.2% | 138.2% | 29.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.58 | -1.14 | -0.43 | 0.12 | 0.54 |
Avg | -1.78 | -1.74 | -1.18 | 0.11 | 0.52 |
Low | -1.89 | -2.11 | -1.80 | 0.11 | 0.50 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 377.3% |
Avg | - | - | - | - | 363.6% |
Low | - | - | - | - | 345.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.